A small Canadian company has waded into a U.S. drug price controversy by offering to make an expensive prostate cancer drug for a fraction of the price. Biolyse Pharma initially made the offer to make a cheaper version of Xtandi (enzalutamide) to the U.S. government in April. Used by a minority of prostate cancer patientsEnzalutamide is commonly prescribed to men who no longer respond to traditional prostate cancer treatments and prevents the hormone testosterone from fuelling the growth of cancer. Of the overall population of men with prostate cancer, only a minority fall into that category. "It's a drug that definitely has had a significant impact on men who, unfortunately, develop this late-stage prostate cancer," he said.

Source: CBC News August 31, 2016 21:56 UTC